Overview

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.

Phase:

Phase 1

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Citalopram
Dexetimide
Methylphenidate
Serotonin Uptake Inhibitors